Balanced news tone
News Sentiment
CLYM sentiment intelligence
Climb Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+8.5% over one week, +22.4% over four weeks, trend active, and materially above fair value.
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 15 Jul 2026 00:59
- Source
- GuruFocus
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Form 4 Climb Bio Inc For: 1 July By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 21:57
- Source
- Investing.com UK
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 08:15
- Source
- MT Newswires
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan
Form 4 Climb Bio Inc For: 30 June By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 00:02
- Source
- Investing.com UK
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 21:45
- Source
- marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 08:46
- Source
- marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Growth Benchmark
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Jun 2026 07:00
- Source
- marketscreener.com
Climb Bio stock price target reiterated at $20 by H.C. Wainwright
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 24 Jun 2026 07:00
- Source
- Investing.com
Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jun 2026 12:11
- Source
- MT Newswires
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 11:00
- Source
- GlobeNewswire
BTIG raises Climb Bio stock price target to $20 on ITP trial data
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 11 Jun 2026 07:00
- Source
- Investing.com
Guggenheim Initiates Climb Bio at Buy With $35 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 08 Jun 2026 10:19
- Source
- MT Newswires
Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Barchart.com
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jun 2026 11:00
- Source
- GlobeNewswire
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 11:00
- Source
- GlobeNewswire
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 05:02
- Source
- MarketBeat
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 11:00
- Source
- GlobeNewswire
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Climb Bio to Present at Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 11:00
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
$110M financing gives Climb Bio room for multiple 2026 drug data readouts
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Market source
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Market source
Institutional investors commit $110M in Climb Bio share sale
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Stock Titan
Climb Bio, Inc. Announces $110.0 Million Private Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source